March 16, 2021 05:17 AM EDTUpdated 09:53 AM
R&D

No quick re­demp­tion for Glax­o­SmithK­line’s $4B al­liance with Mer­ck KGaA as bis­pe­cif­ic can­cer drug flunks a sec­ond tri­al

Amber Tong

Glax­o­SmithK­line’s $4 bil­lion bis­pe­cif­ic can­cer drug al­liance is tak­ing an­oth­er hit.

Just weeks af­ter re­veal­ing a Phase III set­back in non-small cell lung can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

A service from the Financial Times